Skip to main content

2 Result(s)

within Daria Glaessgen Remove this filter

and

  1. Article

    Open Access

    Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c+ Expression in Tumor

    Mesothelin (MSLN) is overexpressed in several tumors including ovarian cancer and is the target of current trials. There is limited and conflicting data on MSLN prognostic impact in ovarian cancer.

    Isabelle Magalhaes, Josefin Fernebro, Sulaf Abd Own, Daria Glaessgen… in Advances in Therapy (2020)

    Download PDF (807 KB) View Article

  2. Article

    Open Access

    Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer

    Mutation in the tumor suppressor gene TP53 is an early event in the development of high-grade serous (HGS) ovarian cancer and is identified in more than 96 % of HGS cancer patients. APR-246 (PRIMA-1MET) is the fi...

    Åsa Fransson, Daria Glaessgen, Jessica Alfredsson… in Journal of Ovarian Research (2016)

    Download PDF (845 KB) View Article